Flibanserin Study Results Announced
Written by Jamie Stowe | Tuesday, 17 November 2009 | There are 0 comments
an increase in the number of Satisfying Sexual Events 
The number of Satisfying Sexual Events recorded by women using the experimental female sexual dysfunction medication flibanserin was considerably greater than those using a placebo and the amount of distress linked to the suffering of Hypoactive Sexual Desire Disorder (HSDD) was significantly reduced too. This information comes from the phase three clinical trial undertaken by the manufacturer of flibanserin, namely Boehringer Ingelheim who have just released their much awaited findings at the 12th Congress of the European Society for Sexual Medicine happening in Lyon, France.
The study which was done on premenopausal women over a six month period saw an increase in the number of SSE’s from 2.8 to 4.5 by the end of the study period compared to 2.7 to 3.7 for the placebo. Interestingly not only did the drug produce more frequent SSE’s but it also produced higher levels of sexual desire in the women participants when compared to those using the placebo. The 1,400 women who took part in the study generally tolerated the flibanserin well and adverse events were reported at fifteen percent compared to seven percent for the placebo. Adverse events included drowsiness, dizziness, general tiredness, anxiety, a dry mouth, nausea and insomnia.
The results were recorded using an eDiary which reminded volunteers to record all details of their sexual desire and sexual activity as well as making use of the precise Female Sexual Function Index (FSFI). Professor Anita Clayton from the University of Virginia and who was co author of this study said that the results showed “exciting progress” in the research of female sexual dysfunction and its possible treatment using flibanserin. She described female sexual dysfunction as an “under recognised condition”. Peter Piliero from Boehringer Ingelheim said that sexual desire problems could affect all women and commented that this new data provided “valuable scientific knowledge about HSDD”.
At present the only medication licenced to treat female sexual dysfunction in the United Kingdom is the drug Intrinsa.
